Methylethyltryptamine
Chemical compound
From Wikipedia, the free encyclopedia
Methylethyltryptamine (MET), also known as N-methyl-N-ethyltryptamine (N,N-MET), is a psychedelic drug of the tryptamine family.[1][4] It is taken orally or via inhalation.[1][3]
- None
 | |
 | |
| Clinical data | |
|---|---|
| Other names | MET; N-Methyl-N-ethyltryptamine; N,N-MET |
| Routes of administration | Oral; Vaporized/inhaled[1][2][3] |
| Drug class | Serotonergic psychedelic; Hallucinogen; Serotonin 5-HT2A and 5-HT2C receptor agonist; Serotonin releasing agent |
| ATC code |
|
| Pharmacokinetic data | |
| Onset of action | Unknown[1] |
| Duration of action | Unknown[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C13H18N2 |
| Molar mass | 202.301 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
The drug acts as an agonist of the serotonin 5-HT2 receptors and to a lesser extent as a serotonin releasing agent.[5] It is closely related to dimethyltryptamine (DMT) and to diethyltryptamine (DET).[6][7]
MET appears to have been first described in the literature in 1981.[8] It was only briefly mentioned in Alexander Shulgin's 1997 book TiHKAL (Tryptamines I Have Known and Loved).[1] The drug was encountered as a novel designer drug in Europe in 2014.[9]
Use and effects
MET was briefly mentioned in Alexander Shulgin's TiHKAL (Tryptamines I Have Known and Loved) and other publications, where he has stated it to be orally active as a psychedelic at doses of 80 to 100 mg.[1][4][2] Its duration, onset, and peak were not provided.[1] The free base of MET has been reported to be active as a psychedelic via vaporization at a dose of 15 mg per informal anecdotal reports.[2][3] Very little information is available on the effects of MET.[2] However, its effects have been reported to include hallucinations, euphoria, tactile enhancement, cognitive effects, pupil dilation, muscle cramps, teeth grinding, and increased heart rate and blood pressure.[2]
Interactions
Pharmacology
Pharmacodynamics
MET is a serotonin 5-HT2A and 5-HT2C receptor partial agonist.[5] It shows very weak activity as an agonist of the serotonin 5-HT1A and 5-HT2B receptors.[5] In addition to acting at the serotonin 5-HT2 receptors, MET is a serotonin releasing agent with lower potency.[5] It produces the head-twitch response, a behavioral proxy of psychedelic effects, in animals.[7][5]
Chemistry
MET, also known as N-methyl-N-ethyltryptamine, is a substituted tryptamine derivative.[1][4][5] It is closely related to N,N-dimethyltryptamine (DMT) and to other N,N-dialkylated tryptamines.[1][4][5]
Analogues
Analogues of MET besides DMT include DET, DPT, DiPT, DBT, MiPT, MBT, EPT, EiPT, and PiPT, among others.[1][4] Derivatives of MET include 4-HO-MET, 5-HO-MET, 5-MeO-MET, bretisilocin (5-fluoro-MET; GM-2505), and 7-F-5-MeO-MET, among others.[1][4]
History
MET appears to have first been described in the literature by 1981.[8] It was specifically mentioned in Michael Valentine Smith's Psychedelic Chemistry.[8] Subsequently, MET was briefly described in Alexander Shulgin's TiHKAL (Tryptamines I Have Known and Loved) in 1997.[1] MET was encountered as a novel designer drug in Europe in 2014.[9]
Society and culture
Legal status
Canada
MET is not a controlled substance in Canada as of 2025.[10]
United States
MET is not an explicitly controlled substance in the United States.[11] However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.
See also
- Substituted tryptamine
- Bretisilocin (5-fluoro-MET; GM-2505)